Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Global Market Value Of The Histone Deacetylase (HDAC) Inhibitors Industry In 2025?
The histone deacetylase (hdac) inhibitors market size has demonstrated significant growth in recent years. This market is projected to expand from $1.23 billion in 2024 to $1.32 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.6%. The expansion observed in the historical period is attributable to several factors, including an increase in funding for epigenetic research, the rising prevalence of drug-resistant cancers, an uptick in healthcare expenditure, the increasing application of HDAC inhibitors in veterinary medicine, and heightened investment in bioinformatics.
The histone deacetylase (hdac) inhibitors market size is projected to experience robust expansion in the coming years. By 2029, it is anticipated to reach $1.76 billion, exhibiting a compound annual growth rate (CAGR) of 7.4%. This anticipated growth during the forecast period stems from factors such as the increasing prevalence of neurodegenerative conditions, heightened awareness regarding cancer, augmented investment in drug development, an expanding volume of clinical trials, and the wider embrace of personalized medicine. Key developments expected during this period encompass technological innovations, individualized treatment approaches, collaborative efforts with cancer immunotherapy, the incorporation of digital health solutions, and advancements in bioinformatics.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18386&type=smp
Which Drivers Are Supporting Growth Of The Histone Deacetylase (HDAC) Inhibitors Market?
The increasing occurrence of neurodegenerative conditions is anticipated to drive expansion in the histone deacetylase (HDAC) inhibitors market in the future. These disorders, involving the gradual deterioration and demise of neurons within the brain and spinal cord, result in impaired cognitive and motor functions. Examples include Alzheimer’s disease, identifiable by memory loss and a decline in cognitive abilities, attributed to amyloid plaques and tau tangles. The growing prevalence of neurodegenerative diseases stems from various elements, including age, increased lifespan, genetic predispositions, and environmental influences. Histone deacetylase (HDAC) inhibitors are currently under investigation as potential therapeutic options for neurodegenerative conditions, given their capacity to modify gene expression and offer neuroprotective benefits. As an illustration, in August 2024, data from the Centers for Disease Control and Prevention, a US-based federal agency, indicated that approximately 6.7 million elderly individuals in the United States currently suffer from Alzheimer’s disease, with projections showing this figure could climb to almost 14 million by 2060. Consequently, the increasing occurrence of neurodegenerative disorders is fueling the expansion of the histone deacetylase (HDAC) inhibitors market.
How Is The Histone Deacetylase (HDAC) Inhibitors Market Classified Into Different Segments?
The histone deacetylase (hdac) inhibitorsmarket covered in this report is segmented –
1) By Class: Class I HDACs; Class II HDACs; Class III HDACs; Class IV HDACs
2) By Route Of Administration: Oral HDAC Inhibitors; Parenteral HDAC Inhibitors
3) By Application: Oncology; Neurology; Other Applications
4) By End User: Hospitals; Academic And Research Institutes; Pharmaceutical Companies; Other End Users
Subsegments:
1) By Class I HDACs: HDAC1; HDAC2; HDAC3; HDAC8
2) By Class II HDACs: HDAC4; HDAC5; HDAC6; HDAC7; HDAC9; HDAC10
3) By Class III HDACs (Sirtuins): SIRT1; SIRT2; SIRT3; SIRT4; SIRT5; SIRT6; SIRT7
4) By Class IV HDACs: HDAC11
What Trends Are Redefining The Histone Deacetylase (HDAC) Inhibitors Market Dynamics?
Companies heavily involved in the histone deacetylase (HDAC) inhibitors market are dedicated to creating advanced solutions, particularly HDAC inhibitors for cancer treatment, to boost effectiveness and lessen adverse reactions. Histone deacetylase (HDAC) inhibitors constitute a category of pharmaceutical compounds employed in cancer therapy. They function by blocking the activity of HDAC enzymes, which typically remove acetyl groups from histone proteins. This inhibition leads to an increase in histone acetylation, consequently modifying chromatin structure and influencing gene expression. For example, in September 2023, Shuttle Pharmaceuticals Holdings Inc., a US-based company that develops first-in-class therapies for cancer, was granted New HDAC Inhibitor Patents for Cancer Treatment by the U.S. Patent and Trademark Office. These innovative inhibitors are designed to target specific HDAC enzymes linked to cancer progression, aiming to disrupt irregular gene expression patterns that contribute to tumor growth and metastasis. The patented compounds exhibit improved potency and selectivity, thereby minimizing off-target effects and enhancing safety profiles for patients undergoing treatment.
Which Industry Leaders Are Driving Innovation Across The Histone Deacetylase (HDAC) Inhibitors Market?
Major companies operating in the histone deacetylase (HDAC) inhibitors market are Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.
Download The Full Report For Exclusive Market Findings:
What Regional Growth Trends Are Shaping The Histone Deacetylase (HDAC) Inhibitors Market Outlook?
North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (HDAC) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Histone Deacetylase (HDAC) Inhibitors Market Report:
https://www.thebusinessresearchcompany.com/customise?id=18386&type=smp
Browse Through More Reports Similar to the Global Histone Deacetylase (HDAC) Inhibitors Market 2025, By The Business Research Company
Her2 Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report
Checkpoint Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report
Protein Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model